Literature DB >> 1716513

Human high-molecular-weight melanoma-associated antigen mimicry by mouse antiidiotypic monoclonal antibody TK7-371.

Z J Chen1, H Yang, T Kageshita, S Ferrone.   

Abstract

Since the human high-molecular-weight melanoma-associated antigen (HMW-MAA) represents a useful target to implement active specific immunotherapy with mouse antiidiotypic monoclonal antibody (mAb), the present study is aimed at developing and characterizing mouse antiidiotypic mAbs which bear the mirror image of the determinant defined by the anti-HMW-MAA mAb TP61.5. To this end, a BALB/c mouse was immunized with the syngeneic mAb TP61.5. Screening of the 703 generated hybridomas showed that 13 of them secrete antiidiotypic mAbs which inhibit the binding of the immunizing mAb TP61.5 to melanoma cells by at least 75%. The dose of antiidiotypic mAb required to inhibit by 50% the binding of mAb TP61.5 to melanoma cells ranged between 4 and 200 ng. The 13 antiidiotypic mAbs recognize conformational idiotypes, since they did not react in Western blotting with the heavy and light chain of mAb TP61.5 isolated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis under reducing conditions. Furthermore, the 13 antiidiotypic mAbs did not react with 23 mAbs which recognize 13 determinants of the HMW-MAA distinct from that defined by mAb TP61.5. Analysis of the 13 antiidiotypic mAbs for their ability to elicit cellular and humoral anti-HMW-MAA immunity showed that only mAb TK7-371 elicited a delayed-type hypersensitivity reaction to HMW-MAA-bearing cells in syngeneic hosts and anti-HMW-MAA antibodies in BALB/c mice and in rabbits. Since rabbits express the HMW-MAA, the present results indicate that the antiidiotypic mAb TK7-371 can induce humoral immunity to self HMW-MAA. Therefore, the antiidiotypic mAb TK7-371 may be an efficacious immunogen to implement active specific immunotherapy in patients with melanoma.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1716513

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

Review 1.  Antithetic roles of proteoglycans in cancer.

Authors:  Elena Garusi; Silvia Rossi; Roberto Perris
Journal:  Cell Mol Life Sci       Date:  2011-10-02       Impact factor: 9.261

2.  CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer.

Authors:  Xinhui Wang; Takuya Osada; Yangyang Wang; Ling Yu; Koichi Sakakura; Akihiro Katayama; James B McCarthy; Adam Brufsky; Mamatha Chivukula; Thaer Khoury; David S Hsu; William T Barry; H Kim Lyerly; Timothy M Clay; Soldano Ferrone
Journal:  J Natl Cancer Inst       Date:  2010-09-17       Impact factor: 13.506

3.  Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma.

Authors:  A Mittelman; Z J Chen; H Yang; G Y Wong; S Ferrone
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-15       Impact factor: 11.205

4.  Enrichment of CD56(dim)KIR + CD57 + highly cytotoxic NK cells in tumour-infiltrated lymph nodes of melanoma patients.

Authors:  Talib Hassan Ali; Simona Pisanti; Elena Ciaglia; Roberta Mortarini; Andrea Anichini; Cinzia Garofalo; Rossana Tallerico; Mario Santinami; Elio Gulletta; Caterina Ietto; Mario Galgani; Giuseppe Matarese; Maurizio Bifulco; Soldano Ferrone; Francesco Colucci; Alessandro Moretta; Klas Kärre; Ennio Carbone
Journal:  Nat Commun       Date:  2014-12-04       Impact factor: 14.919

Review 5.  Antibody therapies for melanoma: new and emerging opportunities to activate immunity (Review).

Authors:  Sadek Malas; Micaela Harrasser; Katie E Lacy; Sophia N Karagiannis
Journal:  Oncol Rep       Date:  2014-06-20       Impact factor: 3.906

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.